

Drug Utilization Review Board

Meeting Minutes

Thursday, April 12, 2018
7:15 a.m. to 8:30 a.m.
Cannon Health Building
Room 125

Board Members Present:

Aesha Drozdowski, Pharm.D.
Eric Cannon, Pharm.D., FAMCP
Jennifer Brinton, M.D.
Katherine Smith, Pharm.D.

Kim Michelson, D.D.S.
Neal Catalano, Pharm.D.
Steve Lore, M.D.
Susan Siegfried, M.D.

Board Members Excused:

Kumar Shah, M.Sc., P.Eng., Board Chair
Ben Berrett, Pharm.D.

Sharon Weinstein, M.D.

Dept. of Health/Div. of Health Care Financing Staff Present:

Andrea Rico, CPhT
Bryan Larson, Pharm.D.
Robyn Seely, Pharm.D.

Heather Santacruz, R.N., PA
Merelynn Berrett, R.N., PA

University of Utah Drug Regimen Review Center Staff Presenter:

Valerie Gonzales, Pharm.D., Clinical Pharmacist

Other Individuals Present:

Elena Martinez Alonso, U of U
Charissa Anne, J&J

Cody Ball, SelectHealth
Andy Killpack, SelectHealth

Meeting conducted by: Robyn Seely

- 1. Welcome & Housekeeping:** Robyn Seely opened the meeting and reminded everyone to sign the rosters.
- 2. Review and Approval of March Minutes:** Kim Michelson made a motion to Approve the minutes as amended from March. Susan Siegfried seconded the motion. Six in favor, Neal Catalano abstained; motion passed. Steve Lore did not vote.
- 3. Nine Month Review: Benzodiazepine Quantity limits**
 - a. Information:** Robyn Seely recommended no changes to the current limits.
 - b. Public Comment:** N/A
 - c. Board Discussion:** None
 - d. Board Action:** None

4. Synagis:

a. Information:

Valerie Gonzales presented a review of Synagis for the treatment of respiratory syncytial virus (RSV) in children 2 years and younger. She presented peer-reviewed research regarding its safety and efficacy, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.

b. Public Comment: None

c. Board Discussion:

Utah Medicaid data shows a claim for an adult patient over 50 years old. Jennifer Brinton asked Valerie Gonzales if there is any data regarding Synagis use in the adult population. Valerie Gonzales replied that there is not.

Jennifer Brinton observed that RSV poses problems to infants and small children due to their small airways and inability to handle excretions. Steve Lore asked Jennifer Brinton if she has experience using Synagis in patients 3 years old and greater. Jennifer Brinton and Katherine Smith observed that Synagis is not recommended or needed for most infants, even with complications such as cystic fibrosis or those that are non-critically premature.

Robyn Seely clarified that the purpose of this discussion is to gauge the Board's ongoing support of the Synagis PA criteria as it stands. It currently aligns with American Association of Pediatricians' guidelines. Jennifer Brinton highlighted Valerie Gonzales' table comparing Food and Drug Administration (FDA)-approval and guidelines, as included in the written report.

Valerie Gonzales clarified that the guidelines and FDA-approved use provide for up to a maximum of 5 doses per season, and that fewer doses are sufficient and appropriate for many patients.

Susan Siegfried observed that the Synagis prior authorization (PA) criteria are some of Utah Medicaid's most complex. Provider education should occur before the RSV season begins so that any PA requests (and any subsequent hearings) are evaluated before the season begins. Note that Utah Medicaid is required to respond to all PA requests within one business day.

The table in the drug monograph comparing Synagis' FDA-approved indications and guidelines was discussed, particularly regarding various patient age and concomitant conditions.

d. Board Action:

1. Change the third bullet on the current criteria to say “less than 12 months and,” rather than “or.” This clarifies that a patient must have one of the conditions described in subsequent bullets, not all of the conditions.

Motion: Jennifer Brinton; Second: Steve Lore; Unanimous

2. Accept the criteria with the amendment above. Motion: Steve Lore; Second: Katherine Smith; Unanimous.

5. **Public Meeting Adjourned:** Eric Cannon motioned to close the meeting. Neal Catalano seconded the motion. Unanimous Approval.

6. **The next meeting scheduled for** Thursday, May 10, 2018 Luxturna.

Audio recordings of DUR meetings are available online at:
<https://medicaid.utah.gov/pharmacy/drug-utilization-review-board?p=DUR%20Board%20Audio%20Recordings/>